Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials

References

• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
   PubMed Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071.
   PubMed Web of Science ®Google Scholar
• Korman NJ, Zhao Y, Li Y, et al. Clinical symptoms and self-reported disease severity among patients with psoriasis – implications for psoriasis management. J Dermatolog Treat. 2015;26(6):514–519.
   PubMed Web of Science ®Google Scholar
• Ljosaa TM, Rustoen T, Mork C, et al. Skin pain and discomfort in psoriasis: an exploratory study of symptom prevalence and characteristics. Acta Derm Venerol. 2010;90(1):39–45.
   PubMed Web of Science ®Google Scholar
• Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323–332.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Paul C, the JUNCTURE study group, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–1090.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, the FEATURE Study Group, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–493.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luger T, Thaçi D, et al. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017;177(4):1033–1042.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Vender R, Kircik L. Secukinumab in the treatment of palmoplantar, nail, scalp, and pustular psoriasis. J Clin Aesthet Dermatol. 2016;9(6 Suppl 1):S12–S16.
   PubMedGoogle Scholar
• Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890–897.
   PubMed Web of Science ®Google Scholar
• EuroQol G. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.
   PubMed Web of Science ®Google Scholar
• Kircik L, Fowler J, Weiss J, et al. Efficacy of secukinumab for moderate-to-severe head and neck psoriasis over 52 weeks: pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2016;6(4):627–638.
   PubMed Web of Science ®Google Scholar
• Menter A, Cather JC, Jarratt M, et al. Efficacy of secukinumab on moderate-to-severe plaque psoriasis affecting different body regions: a pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2016;6(4):639–647.
   PubMed Web of Science ®Google Scholar
• Strober B, Zhao Y, Tran MH, et al. Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis. Int J Dermatol. 2016;55(3):e147–e155.
   PubMed Web of Science ®Google Scholar
• Strober B, Sigurgeirsson B, Popp G, et al. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016;55(4):401–407.
   PubMed Web of Science ®Google Scholar
• Korman NJ, Sofen H, Fretzin S, et al. Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. J Dermatolog Treat. 2017;28(5):384–389.
   PubMed Web of Science ®Google Scholar
• Elewski BE, Puig L, Mordin M, et al. Psoriasis patients with Psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatolog Treat. 2017;28(6):492–499.
   PubMed Web of Science ®Google Scholar
• Geale K, Henriksson M, Schmitt-Egenolf M. How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden. Health Qual Life Outcomes. 2017;15(1):151.
   PubMedGoogle Scholar
• Norlin JM, Steen Carlsson K, Persson U, et al. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol. 2012;166(4):797–802.
   PubMed Web of Science ®Google Scholar
• Masaki S, Tatsukawa R, Uryu M, et al. Treatment satisfaction, willingness to pay and quality of life in Japanese patients with psoriasis. J Dermatol. 2017;44(2):143–146.
   PubMed Web of Science ®Google Scholar
• Moradi M, Rencz F, Brodszky V, et al. Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey. Arch Iran Med. 2015;18(3):153–159.
   PubMed Web of Science ®Google Scholar
• Herédi E, Rencz F, Balogh O, et al. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ. 2014;15(S1):S111–S119.
   Web of Science ®Google Scholar
• Pickard AS, Gooderham M, Hartz S, et al. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. J Med Econ. 2017;20(1):19–27.
   PubMed Web of Science ®Google Scholar